Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies

Shinichi Kako, Shin-ichiro Fujiwara, Yuhei Nakamura et al. Nov 03, 2025 pp. 5995-5995 10.1182/blood-2025-5995

Abstract [Background] We have been performing allogeneic hematopoietic stem cell transplantation from haploidentical related donor using ant...

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Gloria Iacoboni, Victor Navarro, Ana Africa Martin Lopez et al. Nov 03, 2025 pp. 1944-1944 10.1182/blood-2025-1944

Abstract Introduction: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS...

Allogeneic CAR-T therapy AVC-201 in AML positive for CD123

Martin Wermke, Joerg Westermann, Stephan Metzelder et al. Nov 03, 2025 pp. 3426-3426 10.1182/blood-2025-3426

Abstract Introduction: CAR-T therapy in AML has been limited by the absence of ideal target antigens, heterogeneity of the disease, and aggre...

Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases

Dorann Bartebin, Jérome Hadjadj, Laure Croisille et al. Nov 03, 2025 pp. 2984-2984 10.1182/blood-2025-2984

Abstract Introduction: Autoimmune neutropenia (AIN) is a rare and poorly described condition in adults. It may be associated or not with aut...

Hermansky-pudlak syndrome and prolonged activated partial thromboplastin time

Mala Varma, Ilan Shapira Nov 03, 2025 pp. 6598-6598 10.1182/blood-2025-6598

Abstract A patient with a history of oculocutaneous albinism and easy bruising and a family history of the same presented to our health care...

Lived experience of pregnant patients with sickle cell disease: A qualitative study

Lindsey Zhang, Vesna Karadjole, Andrea Simpson et al. Nov 03, 2025 pp. 2954-2954 10.1182/blood-2025-2954

Abstract Sickle Cell Disease (SCD) is an inherited blood disorder. It is marked by end-organ effects and increased pregnancy complications....

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Guru Subramanian Guru Murthy, Yasmin Abaza, Somedeb Ball et al. Nov 03, 2025 pp. 239-239 10.1182/blood-2025-239

Abstract Background: Hypomethylating agent (HMA) with venetoclax (VEN) is used in clinical practice for frontline management of patients wit...

Characterizing Hodgkin lymphoma survivors' shared decision making across the care continuum

Raymond Mailhot Vega, M Devyn Mullis, Carla Fisher et al. Nov 03, 2025 pp. 6424-6424 10.1182/blood-2025-6424

Abstract Introduction: With multiple stage-based treatment options like systemic treatment alone, combined modality therapy, and immunothera...

Real-world comparison of progression-free and overall survival between idecabtagene vicleucel (ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma

Krina Patel, Jenny Chen, Devender Dhanda et al. Nov 03, 2025 pp. 4563-4563 10.1182/blood-2025-4563

Abstract Introduction: Patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) have historically experienced po...

Thrombotic microangiopathy among hospitalized patients: Demographic characteristics, diagnostic trends, and resource use from a national database study

Christopher Poletes, Heng Jiang, Deepika Dilip et al. Nov 03, 2025 pp. 3111-3111 10.1182/blood-2025-3111

Abstract Introduction Thrombotic microangiopathy (TMA) is an uncommon but serious class of microvascular disorders with the ability to lead t...

Once-weekly carfilzomib (56 mg/m²), pomalidomide, and dexamethasone (K56Pd) in patients with first-relapsed multiple myeloma: a Multicenter, prospective, Real-world evidence from China

Fang Jiang, Xiaotao Wang, Yuchan He et al. Nov 03, 2025 pp. 7569-7569 10.1182/blood-2025-7569

Abstract Introduction: Carfilzomib (CFZ) and pomalidomide maintain clinical efficacy in relapsed/refractory multiple myeloma (RRMM). The pha...

No CARs for miles: Geographic disparities in access to multiple myeloma CAR-T therapy

Michael Daunov, Olga Lytvynova, R. Benjamin Gorham et al. Nov 03, 2025 pp. 2816-2816 10.1182/blood-2025-2816

Abstract Introduction Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment for relapsed/refract...

“Suffering in Silence”: Caregiver and medical team experiences on psychosocial screening among pediatric patients with hematologic malignancies

Maitha Ali, Geetika Verma, Sarah Supples et al. Nov 03, 2025 pp. 7921-7921 10.1182/blood-2025-7921

Abstract Background Children diagnosed with hematologic malignancies face physical and psychosocial stressors impacting the entire family. T...

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Naseema Gangat, Ayalew Tefferi, Prithviraj Bose et al. Nov 03, 2025 pp. 2042-2042 10.1182/blood-2025-2042

Abstract Background Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelo...

A series of cryo-EM structures resolves the mechanisms of how factor VIII binds to membranes and to factor IXa on the membrane surface

Vladimir Kolyadko, Ruth Pumroy, Vera Moiseenkova-Bell et al. Nov 03, 2025 pp. 18-18 10.1182/blood-2025-18

Abstract Membranes containing phosphatidylserine are crucial for the assembly of the intrinsic Xase complex of factors VIIIa and IXa at the...

Risk of mental health outcomes and peak risk periods post-hematologic cancer diagnosis in the United States

Tara Beaulieu, Xiaojian Chen, Joanna Gendreau et al. Nov 03, 2025 pp. 4488-4488 10.1182/blood-2025-4488

Abstract Background: Approximately 40% of persons will develop cancer in their lifetime and a considerable proportion of these individuals w...

Determinants of response of the BCMA/GPRC5D-dual-targeting T-cell redirecting trispecific antibody JNJ-5322 in multiple myeloma

Chloe O Neill, Marloes Broekmans, Charlotte Korst et al. Nov 03, 2025 pp. 3922-3922 10.1182/blood-2025-3922

Abstract Introduction BCMA- and GPRC5D-targeting bispecific antibodies (BsAbs) have shown unprecedented clinical efficacy in patients with he...

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Fernando Martin-Moro, Humberto Martinez-Cordero, Guadalupe Antelo Perez et al. Nov 03, 2025 pp. 899-899 10.1182/blood-2025-899

Abstract Background: Plasmablastic lymphoma (PBL) is a rare and aggressive disease, and data on outcomes from large series are limited. A pr...

A tale of two settings: Survival disparities in CLL/SLL between academic and community cancer programs in the u.S. national cancer database

William Ciurylo, Supreet Kaur, Eleftheria Atalla et al. Nov 03, 2025 pp. 4403-4403 10.1182/blood-2025-4403

Abstract Background: Hematologic malignancies are managed at both academic and community-based centers. Studies across solid tumors and bloo...

Evolving use of blast percentage thresholds and classification systems in AML clinical trials (2022–2025): A data-driven trend analysis

Tiantian Zhang, John Choi, Kimo Bachiashvili Nov 03, 2025 pp. 1631-1631 10.1182/blood-2025-1631

Abstract Background: The diagnostic threshold for acute myeloid leukemia (AML) has evolved significantly across classification systems over...

SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease

Su Li, Jun Zhu, Chengwei Jin et al. Nov 03, 2025 pp. 4146-4146 10.1182/blood-2025-4146

Abstract Background: Despite B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies...

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia

Elisa Seubert, Felix Ullrich, Moritz Kruppa et al. Nov 03, 2025 pp. 6936-6936 10.1182/blood-2025-6936

Abstract Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by distinct genetic alterations. The acute promyelo...

Systematic intensification of red cell exchange with hydroxyurea decreased the transfusion burden in patients with sickle cell disease: A single-center retrospective cohort study

Maria Alexandra Nica, Alexie Pellan-Sayegh, Jules Mercier-Ross et al. Nov 03, 2025 pp. 2961-2961 10.1182/blood-2025-2961

Abstract Sickle cell disease (SCD) is a common and severe inherited hemoglobinopathy affecting millions worldwide. This chronic condition le...

National trends and demographic disparities in mortality due to bleeding disorders in the u.S., 1999–2020

Fnu Bhuvan, Sunitha Geddada, Nagateja Yedida et al. Nov 03, 2025 pp. 4864-4864 10.1182/blood-2025-4864

Abstract Background: Bleeding disorders encompass a diverse group of conditions, from inherited hemophilia to acquired coagulopathies like D...

Analysis of efficacy and prognostic factors in transfusion-dependent thalassemia following allogeneic hematopoietic stem cell transplantation using the ‘gx-07-tm’ regimen

Hongwen Xiao, Lingling Shi, Zhenbin Wei et al. Nov 03, 2025 pp. 167-167 10.1182/blood-2025-167

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for transfusion-dependent...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page